Navigation Links
Omeros Corporation Reports Third Quarter 2013 Financial Results
Date:11/7/2013

er 30, 2013, total (i.e., cash and non-cash) operating expenses, excluding the litigation expense, increased by $3.1 million compared to the same period in 2012. The increase was primarily due to the non-cash rent and stock-based compensation expenses of $3.2 million in 3Q 2013 compared to $576,000 in 3Q 2012. The remaining increases were related to conducting the company's Phase 1 clinical program evaluating OMS824, advancing our MASP-2 program, preparing the New Drug Application (NDA) and Marketing Authorization Application (MAA) for OMS302, planning for the commercial launch of OMS302 in the second half of 2014, and non-recurring legal expenses incurred in connection with the CCIC matter. These higher costs were partially offset by lower overall clinical trial expenses related to the completion of the company's OMS302 Phase 3 clinical program in January 2013 and the completion of the company's first OMS103HP Phase 3 clinical trial in arthroscopic partial meniscectomy patients in December 2012.

Total revenue for the quarter ended September 30, 2013 was $196,000 compared to $1.4 million for the same period in 2012. This decrease was primarily due to lower revenue recognized from the company's GPCR platform development funding agreement with Vulcan Inc. and its affiliate. While research continues under the company's GPCR program, no additional deferred revenue under the Vulcan agreement remains to be recognized after the first quarter of 2013.

For the quarter ended September 30, 2013, Omeros reported a net loss of $13.9 million, or $0.46 per share, inclusive of the above-referenced $3.2 million of non-cash charges equaling $0.11 per share, compared to a net loss of $13.3 million, or $0.51 per share, inclusive of the above-referenced $576,000 of non-cash charges equaling $0.02 per share, for the same period in 2012.

At September 30, 2013, Omeros had cash, cash equivalents and short-term investments of $9.0 million. On October 24, 2013, subseque
'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Omeros Announces Closing of $16.2 Million Registered Direct Offering of Common Stock
2. Omeros to Present at the 12th Annual Needham Healthcare Conference
3. Omeros Corporation Reports Fourth Quarter and Year-End 2012 Financial Results
4. Omeros Announces Enrollment in Phase 1 Clinical Trial Evaluating OMS824
5. Omeros to Present at the 19th Annual Newsmakers in the Biotech Industry Conference
6. Omeros Has Now Unlocked Over Half of the Class A Orphan GPCRs
7. Omeros Announces it has Unlocked 30 Percent of Class A Orphan GPCRs
8. Omeros Announces It Has Unlocked Over 20 Percent of Class A Orphan GPCRs
9. China Cord Blood Corporation to Report Second Quarter and First Half of Fiscal 2014 Financial Results
10. Attention Amarin Corporation plc Investors: Amarin Corporation plc Misled Investors According to a Newly Filed Class Action
11. General Patent Corporation Chairman and CEO Alexander Poltorak Joins Spherix Board Industry veteran and authority on patent law and valuation joins Spherix as director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 2014 ENVIRON , an ... today that Dr. Harvey Clewell III has rejoined ... work closely with senior professionals in ENVIRON’s Health ... serve at The Hamner Institutes for Health Sciences ... where he is Director, Center for Human Health ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 The report ... Chemicals), by Application (Cosmetics & Toiletries, and Soaps & ... to 2019”, has defined and segmented the Fragrance Ingredients ... trends in terms of value. The market has been ... North America, Europe, Asia-Pacific, Latin America, and Rest of ...
(Date:10/30/2014)... (PRWEB) October 30, 2014 2014 ... HCL Industry” is a professional and in-depth research ... provides basic Naltrexone HCL information, including its definition, ... as industry overview. This research covers the international ... as global industry analysis covering macroeconomic environment & ...
(Date:10/30/2014)... 2014 James Sherley says he has been ... stem cell technology since his days as a principal investigator ... the late 1990’s. Sherley founded the ASCTC as a ... all the intellectual property developed in Sherley’s research over the ... Institute of Technology (MIT), and more recently as a senior ...
Breaking Biology Technology:Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 2Internationally recognized health scientist Dr. Harvey Clewell renews association with ENVIRON 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 2Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 3Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 4Fragrance Ingredients Market worth $17,104.21 Million by 2019 - New Report by MarketsandMarkets 5Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 2Naltrexone HCL Market & Nalbuphine HCL Industry Analysis for Global, China Regions Now at DeepResearchReports.com 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 2Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 3Boston’s Adult Stem Cell Technology Center, LLC Introduces A New Technology for Monitoring Previously Elusive Adult Stem Cells 4
... Inc. (Nasdaq: NSTK ) announced today that they ... leader in the production of,plasma products, to develop an ... administered by injection to control and prevent,bleeding in patients ... with our new global partner to evaluate the,feasibility of ...
... new, free white paper,addressing the challenges of ... awaiting combination products manufacturers, is now available,for ... combination products are experiencing dramatic growth, the,convergence ... of regulatory,challenges. Manufacturers must ensure their products ...
... Finesse Solutions, LLC,Santa Clara, CA, a manufacturer ... applications, announced the general release of its,TruBio(TM) IOQ ... guesswork,out of validation and to complement the fully ... of control systems can be expensive and time,consuming, ...
Cached Biology Technology:Nastech Enters Into Feasibility Study to Develop a Non-Injectable Dosage Form of Factor IX to Control Bleeding 2Free White Paper Addresses Challenges of New FDA Regulations Awaiting Combo Product Manufacturers 2Finesse Introduces TruBio(TM) IOQ 2
(Date:10/30/2014)... Bacteria in the gastrointestinal tract fulfill many vital ... same bacteria can induce strong inflammatory responses by ... and enter the bloodstream. , Although acute inflammation ... chronic or systemic inflammation is linked to numerous ... involvement of inflammatory processes in the development of ...
(Date:10/30/2014)... 30 October 2014 Biological membranes are mainly composed ... adsorption of solution ions onto lipid membranes helps ... new study provides a quantitative description of the ... Joanna Kotyńska and Zbigniew Figaszewski from the University ... study describing these findings, just published in ...
(Date:10/29/2014)... and gas production are well over recommended levels in ... journal Environmental Health . High levels of benzene, ... the first to be based on community sampling by ... used to supplement official air-quality monitoring programs. , Unconventional ... readily flow to the surface. This is because they ...
Breaking Biology News(10 mins):Breakdown in gut barriers to bacteria may promote inflammation and craving in alcoholics 2Ion adsorption matter in biology 2Air quality and unconventional oil and gas sites 2Air quality and unconventional oil and gas sites 3
... in Northern Ireland, the number of people surviving the disease ... Each year there are between 50-60 men and women ... have died. The survival rates in Northern Ireland for ... the UK, and its patients are benefiting from improved treatment ...
... In 2012 Wiley-Blackwell, the Scientific, Technical, Medical, and Scholarly ... begin publishing 44 titles new to its journal program, ... collaboration with societies or other organizations. Brand new ... of 2012 include Advanced Healthcare Materials , ...
... 28, 2012) Abstracts are now being accepted for ... Diseases Society of America (IDSA), the Society for Healthcare ... and the Pediatric Infectious Diseases Society (PIDS). ... 2012, in San Diego, CA. With the theme Advancing ...
Cached Biology News:More people surviving cancer in Northern Ireland 2Wiley-Blackwell adds 44 titles to journal publishing program in 2012 2
Request Info...
... Concentration Basement Membrane Extract Cultrex HC20+ ... vivo applications where higher protein concentrations ... strength, and elevated levels of tumor ... of lot-to-lot consistency and controlled protein ...
mitochondrial proteins (human heart) for SDS-polyacrylamide gel electrophoresis *2 mg/mL*...
...
Biology Products: